Class Action Lawsuit Filed Against Cerevel Therapeutics, Bain Capital, and Pfizer
On April 11, 2025, Bronstein, Gewirtz & Grossman, LLC, a leading national law firm, announced the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”), Bain Capital Investors, LLC (“Bain”), and Pfizer, Inc. (“Pfizer”) in the United States District Court for the Southern District of New York. The complaint alleges that the Defendants violated the federal securities laws, specifically Sections 10(b), 14(a), and 20A of the Securities Exchange Act of 1934.
Class Definition
The lawsuit seeks to recover damages on behalf of all persons and entities who:
- (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023, through August 1, 2024, inclusive;
- (b) held shares of Cerevel as of January 8, 2024 (the “Record Date”), and were entitled to vote on the merger of Cerevel and AbbVie Inc. (“AbbVie”), and were damaged by defendants’ violations of Section 14(a) of the Exchange Act;
- (c) sold shares of Cerevel stock contemporaneously with Bain’s purchase of shares on or about October 16, 2023, and were damaged by Bain’s violations of Section 20A of the Exchange Act.
The allegations stem from the proposed merger of Cerevel and AbbVie, which was announced on October 11, 2023. The complaint alleges that the Defendants made false and misleading statements regarding the financial condition and prospects of Cerevel, causing artificially inflated stock prices during the Class Period.
Impact on Individual Investors
If you sold Cerevel common stock during the Class Period or held shares on the Record Date and were damaged by the alleged securities law violations, you may be eligible to participate in the class action lawsuit. The lawsuit aims to recover damages for the losses suffered by affected investors due to the Defendants’ alleged violations.
Global Implications
The filing of this class action lawsuit against Cerevel, Bain Capital, and Pfizer could have significant implications for the investment community, particularly in the biotech sector. The allegations of securities law violations could potentially impact investor confidence in the companies involved and could lead to increased regulatory scrutiny. Furthermore, the outcome of this case could set a precedent for future securities class action lawsuits.
Conclusion
The filing of this class action lawsuit against Cerevel Therapeutics, Bain Capital, and Pfizer is a significant development for investors in the biotech sector. The allegations of securities law violations could potentially lead to substantial damages for affected investors and could have far-reaching implications for the investment community. If you believe you may be eligible to participate in the lawsuit, it is essential to consult with an experienced securities attorney to discuss your legal rights and options.
Stay informed about the latest developments in this case and other securities law matters by visiting the Bronstein, Gewirtz & Grossman, LLC website at
